Log in

Relevant bibliographies by topics / 18F-florbetapir

Contents

Journal articles
Book chapters
Conference papers

Academic literature on the topic '18F-florbetapir'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '18F-florbetapir.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "18F-florbetapir"

1

Lilleker, James B., Richard Hodgson, Mark Roberts, et al. "[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis." Annals of the Rheumatic Diseases 78, no. 5 (2019): 657–62. http://dx.doi.org/10.1136/annrheumdis-2018-214644.

Full text

Abstract:

ObjectivesWith the tools available currently, confirming the diagnosis of inclusion body myositis (IBM) can be difficult. Many patients are initially misdiagnosed with polymyositis (PM). In this observational study at a UK adult neuromuscular centre, we investigated whether amyloid positron emission tomography could differentiate between IBM and PM.MethodsTen patients with IBM and six with PM underwent clinical review, [18F]florbetapir positron emission tomography and MRI of skeletal musculature. Differences in [18F]florbetapir standardised uptake value ratios in skeletal muscle regions of int

APA, Harvard, Vancouver, ISO, and other styles

2

B, Lilleker James, Hodgson Richard, Roberts Mark E, et al. "283 Quantifying muscle amyloid in inclusion body myositis using pet." Journal of Neurology, Neurosurgery & Psychiatry 89, no. 10 (2018): A42.3—A43. http://dx.doi.org/10.1136/jnnp-2018-abn.147.

Full text

Abstract:

ObjectivesInclusion body myositis (IBM) shares some histopathological features with polymyositis (PM). Current investigations have low sensitivity for identification of amyloid deposits that are characteristic of IBM, contributing to frequent misdiagnosis. We compared muscle amyloid content, quantified using a novel positron emission tomography (PET) technique, in IBM and PM.MethodsTen cases with IBM and six controls with PM underwent clinical review, [18F]florbetapir PET/computed tomography, and magnetic resonance imaging (MRI) of whole-body skeletal musculature. [18F]florbetapir standardised

APA, Harvard, Vancouver, ISO, and other styles

3

Golla, Sandeep SV, Sander CJ Verfaillie, Ronald Boellaard, et al. "Quantification of [18F]florbetapir: A test–retest tracer kinetic modelling study." Journal of Cerebral Blood Flow & Metabolism 39, no. 11 (2018): 2172–80. http://dx.doi.org/10.1177/0271678x18783628.

Full text

Abstract:

Accumulation of amyloid beta can be visualized using [18F]florbetapir positron emission tomography. The aim of this study was to identify the optimal model for quantifying [18F]florbetapir uptake and to assess test–retest reliability of corresponding outcome measures. Eight Alzheimer’s disease patients (age: 67 ± 6 years, Mini-Mental State Examination (MMSE): 23 ± 3) and eight controls (age: 63 ± 4 years, MMSE: 30 ± 0) were included. Ninety-minute dynamic positron emission tomography scans, together with arterial blood sampling, were acquired immediately following a bolus injection of 294 ± 32

APA, Harvard, Vancouver, ISO, and other styles

4

Carotenuto, Antonio, Beniamino Giordano, George Dervenoulas, et al. "[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis." European Journal of Nuclear Medicine and Molecular Imaging 47, no. 2 (2019): 366–78. http://dx.doi.org/10.1007/s00259-019-04533-y.

Full text

Abstract:

Abstract Purpose We evaluated myelin changes throughout the central nervous system in Multiple Sclerosis (MS) patients by using hybrid [18F]florbetapir PET-MR imaging. Methods We included 18 relapsing-remitting MS patients and 12 healthy controls. Each subject performed a hybrid [18F]florbetapir PET-MR and both a clinical and cognitive assessment. [18F]florbetapir binding was measured as distribution volume ratio (DVR), through the Logan graphical reference method and the supervised cluster analysis to extract a reference region, and standard uptake value (SUV) in the 70–90 min interval after

APA, Harvard, Vancouver, ISO, and other styles

5

Meng, Huanyu, Shuyu Zheng, Shaicun Yuan, et al. "Hybrid ¹⁸F-florbetapir PET/MRI for assessing myelin recovery in GFAP-A patients." Translational Neuroscience 13, no. 1 (2022): 120–24. http://dx.doi.org/10.1515/tnsci-2022-0223.

Full text

Abstract:

Abstract Glial fibrillary acidic protein astrocytopathy (GFAP-A) is a rare autoimmune disease of the central nervous system that was newly reported in 2016. Previous studies have speculated that the pathological mechanism and clinical outcome of GFAP-A lie in the demyelination of the central nervous system, but due to the limitations of MR, this conclusion has not been further confirmed from the perspective of neuroimaging. A non-invasive, quantitative measurement of demyelination would be clinically valuable, given its critical role in mediating GFAP-A. Here, we report a case in which we use

APA, Harvard, Vancouver, ISO, and other styles

6

Raposo, Nicolas, Mélanie Planton, Patrice Péran, et al. "Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages." Neurology 89, no. 7 (2017): 697–704. http://dx.doi.org/10.1212/wnl.0000000000004228.

Full text

Abstract:

Objective:To assess whether 18F-florbetapir, a PET amyloid tracer, could bind vascular amyloid in cerebral amyloid angiopathy (CAA) by comparing cortical florbetapir retention during the acute phase between patients with CAA-related lobar intracerebral hemorrhage (ICH) and patients with hypertension-related deep ICH.Methods:Patients with acute CAA-related lobar ICH were prospectively enrolled and compared with patients with deep ICH. 18F-florbetapir PET, brain MRI, and APOE genotype were obtained for all participants. Cortical florbetapir standard uptake value ratio (SUVr) was calculated with

APA, Harvard, Vancouver, ISO, and other styles

7

Tedeschi Dauar, Marina, Tharick Ali Pascoal, Joseph Therriault, et al. "Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease." Brain Sciences 13, no. 2 (2023): 232. http://dx.doi.org/10.3390/brainsci13020232.

Full text

Abstract:

Associations between pathophysiological events and cognitive measures provide insights regarding brain networks affected during the clinical progression of Alzheimer’s disease (AD). In this study, we assessed patients’ scores in two delayed episodic memory tests, and investigated their associations with regional amyloid deposition and brain metabolism across the clinical spectrum of AD. We assessed the clinical, neuropsychological, structural, and positron emission tomography (PET) baseline measures of participants from the Alzheimer’s Disease Neuroimaging Initiative. Subjects were classified

APA, Harvard, Vancouver, ISO, and other styles

8

Bailly, Matthieu, Maria Joao Santiago Ribeiro, Johny Vercouillie, et al. "18F-FDG and 18F-Florbetapir PET in Clinical Practice." Clinical Nuclear Medicine 40, no. 2 (2015): e111-e116. http://dx.doi.org/10.1097/rlu.0000000000000666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

de Vries, Bart M., Tessa Timmers, Emma E. Wolters, et al. "Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies." Molecular Imaging and Biology 23, no. 4 (2021): 550–59. http://dx.doi.org/10.1007/s11307-020-01572-y.

Full text

Abstract:

Abstract Purpose The simplified reference tissue model (SRTM) is commonly applied for the quantification of brain positron emission tomography (PET) studies, particularly because it avoids arterial cannulation. SRTM requires a validated reference region which is obtained by baseline-blocking or displacement studies. Once a reference region is validated, the use should be verified for each new subject. This verification normally requires volume of distribution (VT) of a reference region. However, performing dynamic scanning and arterial sampling is not always possible, specifically in elderly s

APA, Harvard, Vancouver, ISO, and other styles

10

Soffers, Frederik, Sarah Ceyssens, Wendi Buffet, Didier de Surgeloose, and Roeland Crols. "18F-Florbetapir PET in Primary Cerebral Amyloidoma." Clinical Nuclear Medicine 45, no. 10 (2020): 838–39. http://dx.doi.org/10.1097/rlu.0000000000003214.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "18F-florbetapir"

1

Ballinger, James R. "18F-Florbetapir." In PET Radiopharmaceuticals. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-10271-4_44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Seiffert, Alexander P., Adolfo Gómez-Grande, Patricia Sánchez-González, et al. "Quantitative Analysis of Brain 18F-fluordesoxyglucose and Early-Phase 18F-florbetapir Positron Emission Tomography." In IFMBE Proceedings. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-31635-8_52.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cattell, Liam, Julia A. Schnabel, Jerome Declerck, and Chloe Hutton. "Investigation of Single- Versus Joint-Modality PET-MR Registration for 18F-Florbetapir Quantification: Application to Alzheimer’s Disease." In Computational Methods for Molecular Imaging. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-18431-9_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Høilund-Carlsen, Poul F., Abass Alavi, and Jorge R. Barrio. "PET/CT/MRI in Clinical Trials of Alzheimer’s Disease." In Advances in Alzheimer’s Disease. IOS Press, 2024. https://doi.org/10.3233/aiad240044.

Full text

Abstract:

With the advent of PET imaging in 1976, 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-PET became the preferred method for in vivo investigation of cerebral processes, including regional hypometabolism in Alzheimer’s disease. With the emergence of amyloid-PET tracers, [11C]Pittsburgh Compound-B in 2004 and later [18F]florbetapir, [18F]florbetaben, and [18F]flumetamol, amyloid-PET has replaced FDG-PET in Alzheimer’s disease anti-amyloid clinical trial treatments to ensure “amyloid positivity” as an entry criterion, and to measure treatment-related decline in cerebral amyloid deposits. MRI has been used

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "18F-florbetapir"

1

Khasayeva, Nigar, Cyrus Eierud, Kyle M. Jensen, et al. "Revealing Alzheimer's Disease Dementia Patterns in [18F]Florbetapir PET with Independent Component Analysis." In 2024 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2024. https://doi.org/10.1109/embc53108.2024.10782873.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Khasayeva, Nigar, Kyle M. Jensen, Cyrus Eierud, Helen Petropoulos, Vince D. Calhoun, and Armin Iraji. "[18F]Florbetapir Pet Uptake Differences in White Matter Across the Alzheimer's Disease Continuum: From Cognitively Normal to MCI and Dementia." In 2025 IEEE 22nd International Symposium on Biomedical Imaging (ISBI). IEEE, 2025. https://doi.org/10.1109/isbi60581.2025.10981043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!